Early-stage breast cancer survival rates improve significantly: study

In reassuring news for patients and doctors, a recent study has shown that most women diagnosed with early stage breast cancer today can expect to become long-term cancer survivors.

The findings, published in The BMJ, show that the average risk of dying from breast cancer in the five years after a diagnosis has fallen from 14% to 5% since the 1990s. For those diagnosed during 2010–15, more than six in 10 women had a five-year risk of 3% or less.

Worldwide, more than 2 million women receive a diagnosis of early breast cancer each year. While the risk of dying from breast cancer in these women has decreased over the past few decades, the extent of this decrease was previously unknown. Also, it was not known whether this decrease applied to groups of women with certain characteristics or whether it applied to all groups.

To address this uncertainty, researchers used data from the National Cancer Registration and Analysis Service to investigate the long-term risks of dying from breast cancer after a diagnosis of early breast cancer.

They included all 512,447 women registered in England with early breast cancer (ie, cancer confined to the breast and possibly the axillary lymph nodes) as their first cancer from January 1993 to December 2015, and who were treated initially with surgery.

Annual breast cancer death rates and cumulative five-year risks were estimated, taking account of time since diagnosis, calendar period of diagnosis, and characteristics such as age, whether the cancer was detected by screening, involvement of lymph nodes, and tumour size and grade. All women were followed until December 2020.

For women with a diagnosis made within each of the calendar periods 1993–99, 2000–04, 2005–09, and 2010–15, the results showed that the annual breast cancer mortality rate was highest during the five years after diagnosis and then declined.

Cumulative five-year breast cancer mortality risk was on average 14.4% for women with a diagnosis made during 1993–99 but only 4.9% for women with a diagnosis made during 2010–15.

Considering just the 156,338 women with a diagnosis during 2010–15, cumulative five-year breast cancer mortality risk varied substantially between women with different characteristics. These included patient age, whether the cancer was detected by screening, whether it had certain receptors, and according to cancer size, grade and the number of lymph nodes involved. It was less than 3% for 62.8% of women but more than 20% for 4.6% of women.

The researchers acknowledged several limitations to the study, including that the observational findings couldn’t determine the specific causes of these reductions in mortality. Data on cancer recurrence were also not available. Further, the study focused on women who were initially treated with surgery and did not include women who received treatment to reduce the size of their cancer before surgery, women whose cancer had already spread, or women diagnosed with more than one cancer.

However, the study does provide a detailed and accurate picture of breast cancer mortality in a complete population of women with early breast cancer for up to 20 years.

As such, it can help “provide patients with early breast cancer, and the clinicians who treat them, with estimates of their likely prognosis based on up-to-date data”, the researchers said.

Image credit: iStock.com/ MarsBars